Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 4
Locations
Japan
Study Type
Interventional
Intervention
empagliflozin 10mg
empagliflozin 25 mg
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion criteria:
- Diagnosis of type 2 diabetes mellitus
- Male and female patients on diet and exercise regimen who are pre-treated with Liraglutide at 0.9 mg/day alone for at least 10 weeks prior to screening must be >=7.0% and <=10.0% at screening
- Male and female patients on diet and exercise regimen who are pre-treated with Liraglutide at 0.9 mg/day and one of oral antidiabetic drug (OAD) for at least 10 weeks prior to Visit 1 must be >=7.0% and <=9.0% at screening and >=7.0% and <=10.0% at placebo run-in
- Male and female patients on diet and exercise regimen who are pre-treated with OAD alone for at least 10 weeks prior to Visit 1 must be >=7.0% and <=10.0% at both screening and placebo run-in
- Age at informed consent must be >=20 years
- BMI at screening must be <=40 kg/m2
- Further inclusion criteria apply
Exclusion criteria:
- Uncontrolled hyperglycaemia with a glucose values >270 mg/dL (>15.0 mmol/L) after an overnight fast during switch/washout/placebo run-in period and confirmed by a second measurement
- Patients who are drug-naïve at screening visit or treat with any of insulin, thiazolidine dione, sodium-glucose co-transporter 2 (SGLT-2) inhibitor within 10 weeks prior to informed consent.
- Acute coronary syndrome, stroke or transient ischemic attack within 12 weeks prior to informed consent
- Indication of liver disease, defined by serum levels of either alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase above 3 x upper limit of normal as determined during screening and/or switch/washout/placebo run-in period
- Impaired renal function, defined as estimated glomerular filtration rate (eGFR) <45 mL/min/1.73m2 (Japanese equation) as determined during screening and/or switch/washout/placebo run-in period
- Further exclusion criteria apply
Sites / Locations
- Kunisaki Makoto Clinic
- Seino I.M. Clinic, Fukushima, I.M.
- Nippon Kokan Fukuyama Hospital
- Nakakinen Clinic
- Kubota Clinic
- Medical Corporation Yuga Higashirinkan Kaneshiro Diabetes Clinic
- Yokohama Minoru Clinic
- Yokkaichi Diabetes Clinic
- Shiraiwa Medical Clinic
- AMC Nishi-umeda Clinic
- OCROM Clinic
- Fukuwa Clinic
- Tokyo-Eki Center-building Clinic
- Minamino Heart Clinic
- ToCROM Clinic
- Shinjuku Research Park Clinic
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
empagliflozin 10 mg
empagliflozin 25 mg
Arm Description
empagliflozin 10 mg tablet and placebo matching empagliflozin 25 mg tablet
empagliflozin 25 mg tablet and placebo matching empagliflozin 10 mg tablet
Outcomes
Primary Outcome Measures
Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment
Percentage of patients with drug-related Adverse events (AEs) during 52 weeks of treatment are presented
Secondary Outcome Measures
Change From Baseline in HbA1c After 52 Weeks of Treatment
Change from baseline in HbA1c after 52 weeks of treatment is presented. Means presented are the adjusted means.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02589626
Brief Title
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
Official Title
A 52-week Randomised, Double-blind, Parallel Group, Safety and Efficacy Study of Empagliflozin Once Daily as add-on Therapy to Glucagon-like Peptide-1 Receptor Agonist in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control
Study Type
Interventional
2. Study Status
Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
October 29, 2015 (Actual)
Primary Completion Date
June 2, 2017 (Actual)
Study Completion Date
June 2, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
65 (Actual)
8. Arms, Groups, and Interventions
Arm Title
empagliflozin 10 mg
Arm Type
Experimental
Arm Description
empagliflozin 10 mg tablet and placebo matching empagliflozin 25 mg tablet
Arm Title
empagliflozin 25 mg
Arm Type
Experimental
Arm Description
empagliflozin 25 mg tablet and placebo matching empagliflozin 10 mg tablet
Intervention Type
Drug
Intervention Name(s)
empagliflozin 10mg
Intervention Type
Drug
Intervention Name(s)
empagliflozin 25 mg
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
For blinding purposes
Primary Outcome Measure Information:
Title
Percentage of Patients With Drug-related Adverse Events (AEs) During 52 Weeks of Treatment
Description
Percentage of patients with drug-related Adverse events (AEs) during 52 weeks of treatment are presented
Time Frame
52 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline in HbA1c After 52 Weeks of Treatment
Description
Change from baseline in HbA1c after 52 weeks of treatment is presented. Means presented are the adjusted means.
Time Frame
baseline and 52 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Diagnosis of type 2 diabetes mellitus
Male and female patients on diet and exercise regimen who are pre-treated with Liraglutide at 0.9 mg/day alone for at least 10 weeks prior to screening must be >=7.0% and <=10.0% at screening
Male and female patients on diet and exercise regimen who are pre-treated with Liraglutide at 0.9 mg/day and one of oral antidiabetic drug (OAD) for at least 10 weeks prior to Visit 1 must be >=7.0% and <=9.0% at screening and >=7.0% and <=10.0% at placebo run-in
Male and female patients on diet and exercise regimen who are pre-treated with OAD alone for at least 10 weeks prior to Visit 1 must be >=7.0% and <=10.0% at both screening and placebo run-in
Age at informed consent must be >=20 years
BMI at screening must be <=40 kg/m2
Further inclusion criteria apply
Exclusion criteria:
Uncontrolled hyperglycaemia with a glucose values >270 mg/dL (>15.0 mmol/L) after an overnight fast during switch/washout/placebo run-in period and confirmed by a second measurement
Patients who are drug-naïve at screening visit or treat with any of insulin, thiazolidine dione, sodium-glucose co-transporter 2 (SGLT-2) inhibitor within 10 weeks prior to informed consent.
Acute coronary syndrome, stroke or transient ischemic attack within 12 weeks prior to informed consent
Indication of liver disease, defined by serum levels of either alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase above 3 x upper limit of normal as determined during screening and/or switch/washout/placebo run-in period
Impaired renal function, defined as estimated glomerular filtration rate (eGFR) <45 mL/min/1.73m2 (Japanese equation) as determined during screening and/or switch/washout/placebo run-in period
Further exclusion criteria apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
Kunisaki Makoto Clinic
City
Fukuoka, Fukuoka
ZIP/Postal Code
819-0168
Country
Japan
Facility Name
Seino I.M. Clinic, Fukushima, I.M.
City
Fukushima, Koriyama
ZIP/Postal Code
963-8851
Country
Japan
Facility Name
Nippon Kokan Fukuyama Hospital
City
Hiroshima, Fukuyama
ZIP/Postal Code
721-0927
Country
Japan
Facility Name
Nakakinen Clinic
City
Ibaraki, Naka
ZIP/Postal Code
311-0113
Country
Japan
Facility Name
Kubota Clinic
City
Kanagawa, Kawasaki
ZIP/Postal Code
214-0014
Country
Japan
Facility Name
Medical Corporation Yuga Higashirinkan Kaneshiro Diabetes Clinic
City
Kanagawa, Yamato-shi
ZIP/Postal Code
242-0004
Country
Japan
Facility Name
Yokohama Minoru Clinic
City
Kanagawa, Yokohama
ZIP/Postal Code
232-0064
Country
Japan
Facility Name
Yokkaichi Diabetes Clinic
City
Mie, Yokkaichi
ZIP/Postal Code
510-0829
Country
Japan
Facility Name
Shiraiwa Medical Clinic
City
Osaka, Kashiwara-shi
ZIP/Postal Code
582-0005
Country
Japan
Facility Name
AMC Nishi-umeda Clinic
City
Osaka, Osaka-shi
ZIP/Postal Code
530-0001
Country
Japan
Facility Name
OCROM Clinic
City
Osaka, Suita
ZIP/Postal Code
565-0853
Country
Japan
Facility Name
Fukuwa Clinic
City
Tokyo, Chuo-ku
ZIP/Postal Code
103-0027
Country
Japan
Facility Name
Tokyo-Eki Center-building Clinic
City
Tokyo, Chuo-ku
ZIP/Postal Code
103-0027
Country
Japan
Facility Name
Minamino Heart Clinic
City
Tokyo, Hachioji
ZIP/Postal Code
192-0918
Country
Japan
Facility Name
ToCROM Clinic
City
Tokyo, Shinjuku-ku
ZIP/Postal Code
160-0022
Country
Japan
Facility Name
Shinjuku Research Park Clinic
City
Tokyo, Shinjuku-ku
ZIP/Postal Code
169-0073
Country
Japan
12. IPD Sharing Statement
Citations:
PubMed Identifier
30912033
Citation
Terauchi Y, Utsunomiya K, Yasui A, Seki T, Cheng G, Shiki K, Lee J. Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study. Diabetes Ther. 2019 Jun;10(3):951-963. doi: 10.1007/s13300-019-0604-8. Epub 2019 Mar 25.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/
Description
Related Info
Learn more about this trial
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
We'll reach out to this number within 24 hrs